Posted by Kinapse on 01 February 2016
Kinapse, a leading global provider of advisory, capability building and operational services to the life sciences industries, today announced a majority investment by HgCapital. HgCapital will back the existing management and assume majority ownership from management shareholders and Synova Capital. The terms of the transaction were not disclosed.
Established ten years ago by Co-Founders Nicholas Edwards, Chairman, and Andy Black, CEO, Kinapse provides advisory, capability building and operational services to the world’s leading life sciences organisations, their customers, suppliers and regulators. The Group has offices in the UK, India and the United States and employs over 500 professionals worldwide. Kinapse is a partner of 9 out of the top 10 global pharma companies.
Kinapse has grown significantly in recent years and has featured on the Sunday Times Fast Track 100 list of the fastest growing companies in the UK for three consecutive years. It recently opened US offices in Chicago, Cambridge and Manhattan and expanded operations and teams in India.
Kinapse plans to continue the current growth trajectory with the backing of a strong investor. HgCapital is a leading private equity fund with a track record of creating sector leaders and has deep expertise in technology-enabled services businesses and the health and life sciences sectors.
Future growth strategies will include driving the US business, entering the Japanese market and creating broader full service solutions enabled by technology. Both organic and inorganic growth opportunities will be considered. The decision to continue competing as an independent entity will allow Kinapse to build upon existing strengths and leverage strong capabilities, people and values.
“We have been deeply impressed by the Kinapse team, who have built the business into one of the leading global pharma regulatory service providers,” said Philipp Schwalber, a Director in the HgCapital Services team. “Through its global offering and strong client base, Kinapse is uniquely positioned in this rapidly expanding global market.”
“I am enormously grateful for the great work of our global team during the past ten years. We have been privileged to work with many industry leaders and to have had fantastic support from Synova Capital since they invested in Kinapse in 2012” said Andy Black, CEO. “We are all delighted to be partnering with Philipp Schwalber and the HgCapital team as we take the business forwards with a vision of achieving sector leadership across our Advise, Build and Operate services.”
Nicholas Edwards, Chairman of Kinapse said: “This investment is a recognition of the success already achieved by Kinapse and provides us with a significant financial partner to support our continuing growth as we work with leading pharmaceutical companies to help them rapidly bring new medicines to patients. We are delighted that our unique model combining advisory and operational services has again been recognised as the best way to support the life sciences industry."
Kinapse was advised by DC Advisory, Deloitte, Taylor Wessing and Jamieson Corporate Finance.
For further details:
UK Office: +44 (0) 208 946 7600
Press Contact: Amanda Swain, firstname.lastname@example.org
Laura Dixon: +44 (0)20 7089 7888
Seda Ambartsumian: +44 (0)20 7379 5151
Jamie Dunkley: +44 (0)20 7379 5151
Advise · Build · Operate